aTyr Pharma, Inc. (LIFE) Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research upgraded shares of aTyr Pharma, Inc. (NASDAQ:LIFE) from a hold rating to a buy rating in a research note released on Wednesday morning. They currently have $3.50 price target on the biotechnology company’s stock.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
A number of other equities analysts also recently commented on LIFE. BMO Capital Markets set a $4.00 price objective on shares of aTyr Pharma and gave the stock a hold rating in a research note on Tuesday, August 15th. ValuEngine downgraded shares of aTyr Pharma from a hold rating to a sell rating in a research note on Tuesday, August 1st. Finally, Piper Jaffray Companies assumed coverage on shares of aTyr Pharma in a research note on Thursday, September 7th. They set an overweight rating and a $7.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $4.27.
Shares of aTyr Pharma (LIFE) traded up 12.12% during mid-day trading on Wednesday, hitting $3.70. The company’s stock had a trading volume of 219,556 shares. The stock’s market cap is $88.20 million. The company has a 50-day moving average price of $3.26 and a 200-day moving average price of $3.45. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $4.45.
aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.51) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.06. Analysts predict that aTyr Pharma will post ($2.18) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/17/atyr-pharma-inc-life-stock-rating-upgraded-by-zacks-investment-research.html.
In other news, Director Paul Schimmel bought 94,336 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was acquired at an average cost of $2.65 per share, for a total transaction of $249,990.40. Following the purchase, the director now owns 40,440 shares of the company’s stock, valued at approximately $107,166. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Mendlein bought 37,736 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average price of $2.65 per share, with a total value of $100,000.40. The disclosure for this purchase can be found here. Company insiders own 33.30% of the company’s stock.
A hedge fund recently raised its stake in aTyr Pharma stock. EcoR1 Capital LLC boosted its position in aTyr Pharma, Inc. (NASDAQ:LIFE) by 134.7% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 2,292,659 shares of the biotechnology company’s stock after purchasing an additional 1,315,673 shares during the period. aTyr Pharma comprises 2.0% of EcoR1 Capital LLC’s holdings, making the stock its 13th largest position. EcoR1 Capital LLC owned about 9.65% of aTyr Pharma worth $8,024,000 at the end of the most recent quarter. 46.66% of the stock is currently owned by institutional investors.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.